5 July 2022
Forterra plc (the "Company")
Director / PDMR Shareholdings
Following the vesting on 12 March 2022 of share options granted to Executive Directors under the 2019 Deferred Annual Bonus Plan ("DABP"), the Company was notified on the 10 May 2022 that on 9 May 2022 the following exercise and sale transactions took place:
Stephen Harrison, Chief Executive Officer exercised options granted under the DABP as laid out below selling sufficient shares to cover the appropriate tax and national insurance liabilities with the balance being retained.
| Name | Status | No. of shares exercised | Sale Date | Number of shares sold | Price | Number of shares retained | Total Shareholding | % of ISC |
| Stephen Harrison | PDMR | 37,891 | 09/05/22 | 18,350 | £2.365 | 19,541 | 285,803 | < 1% |
The 2019 DABP awards represent the deferral into ordinary shares of part of the Executive Directors' 2018 bonus entitlements under the rules of the scheme subject to the participant being an employee at the time of vesting. No consideration was paid for the grant of the awards which are structured as nominal (1p) cost options although this sum was waived by the Company on exercise. The number of options exercised also includes a dividend equivalent in addition to the options initially granted in accordance with the rules of the scheme.
No new shares were issued in respect of these transactions with shares being transferred to the individuals from the Forterra Employee Benefit Trust.
The above notification is intended to satisfy the Company's obligations under Article 19 of the Market Abuse Regulations.
Enquiries
| Forterra plc: | +44 (0) 1604 707 600 |
| Ashley Thompson (Company Secretary) | |
| | |
| FTI Consulting: | +44 (0) 20 3727 1340 |
| Richard Mountain/Nick Hasell | |
Further information relating to the Company and its group can be found at www.forterraplc.co.uk.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
